A pilot trial found medical cannabis feasible and potentially helpful for pain, appetite, and insomnia in pancreatic cancer patients

The trial met all prespecified feasibility benchmarks: 74% enrollment (goal 20%), 81% compliance (goal 60%), and 75% outcome completion (goal 50%). All early-arm participants recommended the intervention. At 8 weeks, early-arm patients showed numerically higher improvement rates for pain (44% vs 20%), appetite (56% vs 30%), and insomnia (67% vs 30%), though none reached statistical significance. Median daily THC use was 7.3 mg. Cannabis-related harms were low.

Pilot randomized waitlist-controlled trial of 32 patients with newly diagnosed locally advanced/metastatic pancreatic adenocarcinoma in Minnesota. Randomized 1:1 to early (weeks 0-8) or delayed (weeks 9-16) cannabis intervention through the Minnesota Medical Cannabis Program. Primary outcome was feasibility.

Pancreatic cancer patients experience severe symptom burden and limited treatment options. This study demonstrates that rigorous cannabis research can be conducted through state program partnerships, offering a path around federal regulatory barriers.

This pilot demonstrates a replicable model for conducting interventional cannabis research within existing state programs. If larger trials confirm these preliminary signals, medical cannabis could become part of supportive care for pancreatic cancer.

Pilot study not powered for efficacy (32 patients). No differences reached statistical significance. Waitlist control, not placebo-controlled. Open-label design subject to expectation bias. Single state program may not generalize.